TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26069272

Group type: EXPERIMENTAL
Intervention: Daily weight monitoring
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 49
Study: 24372937

Group type: COMPARATOR
Intervention: Computer Brief Intervention (CBI)
Number of subjects: 714

Group type: COMPARATOR
Intervention: Therapist Brief Intervention (TBI)
Number of subjects: 714
Study: 23057624

Group type: EXPERIMENTAL
Intervention: 20 units of onabotulinumtoxinA
Number of subjects: 224

Group type: COMPARATOR
Intervention: 30 units of incobotulinumtoxinA
Number of subjects: 224
Study: 17904865

Group type: EXPERIMENTAL
Intervention: Resistance training program based on electromyographic fatigue threshold (EMG(FT))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20
Study: 17907851

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral program (CB)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy-adolescent skills training program (IPT-AST)
Number of subjects: 380

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 380
Study: 15145035

Group type: EXPERIMENTAL
Intervention: Arthroscopy with sodium hyaluronate infusion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Arthrocentesis
Number of subjects: 26
Study: 11896507

Group type: EXPERIMENTAL
Intervention: Treated hypertensive group
Number of subjects: 502

Group type: COMPARATOR
Intervention: Normotensive group
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Daytime BP
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Night-time BP
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Circadian variability
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Office BP
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Sex-specific BP values
Number of subjects: 502
Study: 9564748

Group type: EXPERIMENTAL
Intervention: Deviant tones in the attended ear
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unattended-ear deviants
Number of subjects: 0
Study: 8180671

Group type: EXPERIMENTAL
Intervention: Growth hormone (0.02-0.05 IU/kg body wt sc daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Growth hormone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Growth hormone and Placebo
Number of subjects: 36
Study: 3286830

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 626

Group type: COMPARATOR
Intervention: Chemotherapy plus immunotherapy
Number of subjects: 626

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Acute toxicity
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Delayed toxicity
Number of subjects: 626
Study: 29683855

Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Number of subjects: 725

Group type: COMPARATOR
Intervention: Control (darunavir/cobicistat plus emtricitabine/tenofovir disoproxyl fumarate)
Number of subjects: 725

Group type: COMPARATOR
Intervention: Control
Number of subjects: 725
Study: 26743886

Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystomy (ELC; LC performed within 7 days after a pancreatitis attack)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Late laparoscopic cholecystomy (LLC; LC performed ≥ 7 days following an attack)
Number of subjects: 102
Study: 25539782

Group type: EXPERIMENTAL
Intervention: Virtual Reality-Based Wii Fit exercise (VRWii group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no structured exercise program)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Traditional exercise (TE group)
Number of subjects: 36
Study: 23820947

Group type: EXPERIMENTAL
Intervention: Irrelevant speech
Number of subjects: 0
Study: 20637394

Group type: EXPERIMENTAL
Intervention: Airway scope (AWS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (ML)
Number of subjects: 25
Study: 18252784

Group type: EXPERIMENTAL
Intervention: Phylloquinone supplementation (500 mug/d)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Control group (no phylloquinone)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Both groups (phylloquinone and control)
Number of subjects: 452
Study: 16368298

Group type: EXPERIMENTAL
Intervention: valsartan 80 mg/d
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: valsartan 160 mg/d
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: valsartan 320 mg/d
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: valsartan (all doses)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: valsartan in patients with diabetes
Number of subjects: 75
Study: 12525717

Group type: EXPERIMENTAL
Intervention: Interferon beta (IFNβ)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 33
Study: 10960199

Group type: EXPERIMENTAL
Intervention: Warmed (42 degrees C) humidified O(2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine O(2) therapy (control group)
Number of subjects: 30
Study: 8773861

Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg.kg‐1 and 5 mg.kg‐1 thiopentone (group MT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1 (group P)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg.kg‐1 and 5 mg.kg‐1 thiopentone (group LT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Lidocaine-thiopentone group (group LT)
Number of subjects: 150
Study: 1522692

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6499510

Group type: EXPERIMENTAL
Intervention: Dantrolene sodium (average dose 165.4 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dantrolene sodium
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30620944

Group type: EXPERIMENTAL
Intervention: Visible respiratory function monitor (RFM)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Masked respiratory function monitor (RFM)
Number of subjects: 106
Study: 29760878

Group type: EXPERIMENTAL
Intervention: Activator II™-instrument-assisted cervical and thoracic spine manipulation plus light massage, mobilisation, range of motion exercises, and home advice about heat application
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham-Activator II™-instrument-assisted manipulation (set to zero impulse) plus gentle touch of cervical and thoracic spinal regions
Number of subjects: 24
Study: 26667358

Group type: EXPERIMENTAL
Intervention: Cancer Survivorship Intervention-Sexual Health (CSI-SH)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Assessment Only (AO)
Number of subjects: 70
Study: 24252035

Group type: EXPERIMENTAL
Intervention: BUC + MTX
Number of subjects: 55

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 55
Study: 22256805

Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg once daily) and Asunaprevir (600 mg twice daily) alone (group A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg once daily) and Asunaprevir (600 mg twice daily) in combination with peginterferon alfa‐2a and ribavirin (group B)
Number of subjects: 21
Study: 20410884

Group type: EXPERIMENTAL
Intervention: BMS-790052, a small molecule inhibitor of the HCV NS5A protein, administered as a single 100-mg dose.
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: BMS-790052
Number of subjects: 2
Study: 17380550

Group type: EXPERIMENTAL
Intervention: Essential oil mouthwash (mixture of tea tree, peppermint, and lemon)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Tantum (benzydamine hydrochloride)
Number of subjects: 32
Study: 16356894

Group type: EXPERIMENTAL
Intervention: Abuse assessment and receipt of a wallet-size referral card
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Abuse assessment, receipt of a wallet-size referral card, and nurse case management sessions
Number of subjects: 233

Group type: COMPARATOR
Intervention: Comparison group (clinically-referred sample of children)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Children ages 18 months to 5 years
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Teenagers
Number of subjects: 233
Study: 12048339

Group type: EXPERIMENTAL
Intervention: Patient appointment guidebook
Number of subjects: 277

Group type: COMPARATOR
Intervention: Standard appointment reminder letter
Number of subjects: 277
Study: 10378967

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy
Number of subjects: 0
Study: 7775792

Group type: EXPERIMENTAL
Intervention: Activated charcoal (Group 1)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Saline lavage followed by activated charcoal (Group 2)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Activated charcoal followed by saline lavage followed by activated charcoal (Group 3)
Number of subjects: 51
Study: 2277576

Group type: EXPERIMENTAL
Intervention: 2 ml isobaric tetracaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1 ml isobaric tetracaine
Number of subjects: 100
Study: 6451138

Group type: EXPERIMENTAL
Intervention: Auto-traction treatment for up to three 1-hour sessions in 1 week
Number of subjects: 82

Group type: COMPARATOR
Intervention: Corset and advised to rest (Control)
Number of subjects: 82
Study: 31637733

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levofloxacin (1000 and 1500 mg)
Number of subjects: 0
Study: 29547962

Group type: EXPERIMENTAL
Intervention: One open-label placebo pill per day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Four open-label placebo pills per day
Number of subjects: 100

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 100
Study: 26465101

Group type: EXPERIMENTAL
Intervention: 10% gel of unripe banana peel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (gel containing no active ingredient)
Number of subjects: 60
Study: 23965205

Group type: EXPERIMENTAL
Intervention: Group L (luteal phase)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group F (follicular phase)
Number of subjects: 80
Study: 21665107

Group type: EXPERIMENTAL
Intervention: Flexible foil training for shoulder pain group 1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flexible bands training for shoulder pain group 2
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-symptomatic subjects
Number of subjects: 30
Study: 19332659

Group type: EXPERIMENTAL
Intervention: Physiological sex steroid replacement (transdermal estradiol and vaginal progesterone)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard sex steroid replacement (oral ethinylestradiol and norethisterone)
Number of subjects: 34
Study: 16387822

Group type: EXPERIMENTAL
Intervention: Liberal definition of myocardial infarction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stringent definition of myocardial infarction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TIMI major bleeding definition
Number of subjects: 0
Study: 15884282

Group type: EXPERIMENTAL
Intervention: 200 microg vaginal misoprostol, six hourly for a maximum of four doses
Number of subjects: 38

Group type: COMPARATOR
Intervention: 200 microg oral misoprostol, six hourly for a maximum of four doses
Number of subjects: 38

Group type: COMPARATOR
Intervention: 200 microg oral misoprostol
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 200 microg vaginal misoprostol
Number of subjects: 38
Study: 10695646

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 9084795

Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine (ZDV/3TC)
Number of subjects: 972

Group type: COMPARATOR
Intervention: Control treatments (ZDV or ZDV/zalcitabine)
Number of subjects: 972
Study: 8385971

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 0
Study: 2949027

Group type: EXPERIMENTAL
Intervention: Continuous enteral nutrition
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intermittent enteral nutrition
Number of subjects: 34
Study: 31249174

Group type: EXPERIMENTAL
Intervention: Air dry for 5 seconds
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Blot dry for 10 seconds
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Suction dry for 10 seconds
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Air dry for 2 seconds
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Blot dry for 2 seconds
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Suction dry for 2 seconds
Number of subjects: 135
Study: 29973191

Group type: EXPERIMENTAL
Intervention: High-intensity SC active referral (HAR Group)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Low-intensity SC referral by text messaging (Text Group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: General very brief advice (Control Group)
Number of subjects: 68
Study: 28082820

Group type: EXPERIMENTAL
Intervention: Pronase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24685085

Group type: EXPERIMENTAL
Intervention: LMWH + GCS
Number of subjects: 247

Group type: COMPARATOR
Intervention: GCS
Number of subjects: 247
Study: 22440123

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 350

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 350
Study: 19071038

Group type: EXPERIMENTAL
Intervention: Sodium perborate/37% carbamide peroxide paste
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sodium perborate/distilled water
Number of subjects: 30
Study: 17443465

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B 3 mg/kg per day
Number of subjects: 201

Group type: COMPARATOR
Intervention: Liposomal amphotericin B 10 mg/kg per day
Number of subjects: 201
Study: 15926874

Group type: EXPERIMENTAL
Intervention: Tolvaptan (vasopressin antagonist) in addition to standard therapy including diuretics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy including diuretics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0
Study: 12355980

Group type: EXPERIMENTAL
Intervention: Mass vaccination against smallpox
Number of subjects: 0
Study: 9690953

Group type: EXPERIMENTAL
Intervention: (+)-sotalol 300 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: (+/-)-sotalol 240 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8589322

Group type: EXPERIMENTAL
Intervention: High-osmolar contrast media diatrizoate (D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-osmolar contrast media iopamidol (I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-osmolar contrast media diatrizoate (D) with captopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-osmolar contrast media diatrizoate (D) with nifedipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-osmolar contrast media diatrizoate (D) unpretreated
Number of subjects: 0
Study: 2807841

Group type: EXPERIMENTAL
Intervention: Midline laparotomy (Group A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Supraumbilical transverse laparotomy (Group B)
Number of subjects: 32
Study: 1028632

Group type: EXPERIMENTAL
Intervention: Mazindol (non-amphetaminic anorexiant)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet with anorexiant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mazindol
Number of subjects: 0
Study: 30704697

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600mg twice daily
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) with long-acting inhaled bronchodilator(s) but no ICS
Number of subjects: 964

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 964
Study: 27776269

Group type: EXPERIMENTAL
Intervention: Therapeutic Education System (TES)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Counselor-delivered treatment (Arm 1)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Reduced TAU plus TES (Arm 2)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 507
Study: 24846518

Group type: EXPERIMENTAL
Intervention: Adalimumab with or without calcipotriol plus betamethasone dipropionate
Number of subjects: 730
Study: 23393065

Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg orally) with 8 h of isocapnic hypoxia
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg orally) with 8 h of air breathing
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo with 8 h of isocapnic hypoxia
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo with 8 h of air breathing
Number of subjects: 8
Study: 22040307

Group type: EXPERIMENTAL
Intervention: Pharmacist Intervention Group (PIG)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Usual Care Group (UCG)
Number of subjects: 154
Study: 17923015

Group type: EXPERIMENTAL
Intervention: HES 130/0.4 group (HES group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gelatin group (GEL group)
Number of subjects: 40
Study: 15826230

Group type: EXPERIMENTAL
Intervention: Break duration manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Break location manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reaction time response at the end of the break
Number of subjects: 0
Study: 12039485

Group type: EXPERIMENTAL
Intervention: Elevated cardiac troponin I (cTnI) after PCI
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Elevated cardiac troponin I (cTnI) after PCI (positive only after PCI)
Number of subjects: 481
Study: 10469349

Group type: EXPERIMENTAL
Intervention: Preventive measures to avoid graft injury from immune and nonimmune mechanisms
Number of subjects: 0
Study: 7898689

Group type: EXPERIMENTAL
Intervention: Presence of ischemic lesions observed on CT
Number of subjects: 164

Group type: COMPARATOR
Intervention: No ischemic lesions observed on CT
Number of subjects: 164
Study: 2539403

Group type: EXPERIMENTAL
Intervention: Lisinopril 5 mg orally once per day
Number of subjects: 189

Group type: COMPARATOR
Intervention: Captopril 12.5 mg orally three times per day
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 189

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 189
Study: 35075

Group type: EXPERIMENTAL
Intervention: Totamine synthetic amino acid solution, administered starting two days before surgery, providing 1200 calories and 12.4 g of nitrogen per day.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group receiving Totamine starting on the day of surgery, providing 1200 calories and 12.4 g of nitrogen per day.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (preoperative and postoperative) receiving Totamine.
Number of subjects: 26
Study: 31748198

Group type: EXPERIMENTAL
Intervention: Exercise advice and support (5-10 consultations with a physiotherapist) plus existing telephone service
Number of subjects: 175

Group type: COMPARATOR
Intervention: Existing telephone service (≥1 nurse consultation for self-management advice)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Exercise advice and support
Number of subjects: 175
Study: 31522886

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT) with immediate knowledge of results (KR)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 10-meter walk test (10MWT) with immediate knowledge of results (KR)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 6-minute walk test (6MWT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 10-meter walk test (10MWT)
Number of subjects: 25
Study: 28177733

Group type: EXPERIMENTAL
Intervention: Block training (BL)
Number of subjects: 20
Study: 25722382

Group type: EXPERIMENTAL
Intervention: Tecemotide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tecemotide (in concurrent chemoradiotherapy subgroup)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (in concurrent chemoradiotherapy subgroup)
Number of subjects: 0
Study: 23430455

Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention for weight loss (weekly group sessions for 6 months, followed by 12 months of biweekly contacts)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention for weight loss
Number of subjects: 218
Study: 22052225

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg orally once daily on days 5 to 11)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Levofloxacin and Placebo
Number of subjects: 187
Study: 19481491

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 10
Study: 16391577

Group type: EXPERIMENTAL
Intervention: 800 microg/day folic acid (FA group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 8.4 mg/day riboflavin (R group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both folic acid and riboflavin (FAR group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 32
Study: 15080016

Group type: EXPERIMENTAL
Intervention: Elderberry syrup (15 ml, four times a day for 5 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 60
Study: 12200354

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) and idarubicin regimen (AIDA regimen)
Number of subjects: 51
Study: 9643523

Group type: EXPERIMENTAL
Intervention: Kaposi's sarcoma-associated herpes virus identification in bone marrow stromal cells
Number of subjects: 500
Study: 9522869

Group type: EXPERIMENTAL
Intervention: Glucose-based oral rehydration solution (ORS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rice-based oral rehydration solution (ORS)
Number of subjects: 20
Study: 2672871

Group type: EXPERIMENTAL
Intervention: Homologous fresh frozen plasma (FFP), 2 units (430 +/- 11 ml) given after the end of extracorporeal circulation (ECC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group without FFP
Number of subjects: 40